DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $452.16M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.29M
Average 0.19M
Returns on capital
DiaMedica Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-58.4%
avg -95.0%
ROIC
-61.0%
avg -92.4%
ROA
-53.4%
avg -128.0%
Analysis
ROA is currently the strongest return metric at -53.4% versus its period average of -128.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Dietrich John Pauls | President, Chief Executive Officer & Director | USD 1.07M | 55 | 128.79K | 0.24% |
Julie Krop | Chief Medical Officer | USD 675.67K | 60 | 0 | <0.01% |
Scott Kellen | Chief Financial Officer & Corporate Secretary | USD 609.87K | 61 | 225.00K | 0.42% |
Ambarish Shah | Chief Technology Officer | — | — | — | — |
Dominic R. Cundari | Chief Commercial Officer | — | 75 | 15.00K | 0.03% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$6.41M
Sells
0
$0.00
Net Transaction Value
+$6.41M
Net buying
Most Active
STAHLBERG JAN
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 25, 25Nov 25, 2025 | STAHLBERG JAN Indirect | Buy | $626.8K$626,816.62 |
| Nov 24, 25Nov 24, 2025 | STAHLBERG JAN Indirect | Buy | $317.7K$317,720.95 |
| Nov 21, 25Nov 21, 2025 | STAHLBERG JAN Indirect | Buy | $1.5M$1,547,574.42 |
| Nov 20, 25Nov 20, 2025 | STAHLBERG JAN Indirect | Buy | $951.2K$951,212.85 |
| Nov 19, 25Nov 19, 2025 | STAHLBERG JAN Indirect | Buy | $1.7M$1,732,361.08 |
| Nov 18, 25Nov 18, 2025 | STAHLBERG JAN Indirect | Buy | $1.2M$1,234,618.09 |
Summary
Insiders reported 6 buys worth $6.41M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $6.41M. STAHLBERG JAN was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does DiaMedica Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DMAC's management, answered from reported figures.
Who manages DMAC?
DiaMedica Therapeutics Inc. (DMAC) lists 5 active executives. The top listed executive is Ambarish Shah, Chief Technology Officer.
Are DMAC insiders buying or selling?
Recent insider activity shows net buying of $65.29M.
Continue the stock analysis
Jump to another research area for this company.